Pfizer Forecasts $54 Billion In Sales This Year As Demand For COVID-19 Vaccine And Treatment Pill Continues

Pfizer on Tuesday said it expects to see continued demand for its products this year, forecasting $54 billion in combined sales of its COVID-19 vaccine shots and antiviral pills. The American pharmaceutical and biotechnology giant said it expects to sell $32 billion of its vaccinations and $22 billion of its antiviral COVID-19 treatment pill Paxlovid in 2022 as demand for the products continues. Those numbers are based on contracts signed or close to being signed as of late January, Pfizer said. Paxlovid was authorized for emergency use by the U.S. Food and Drug Administration (FDA) in December and is aimed at helping patients who are suffering from “mild-to-moderate” COVID-19 symptoms from becoming so sick that they need to be hospitalized, Pfizer has said. In its Fourth-Quarter and Full-Year 2021 Results forecast, Pfizer said increased sales of its COVID-19 treatments will see its revenue boosted to around $100 billion this year. Overall,  » Read full article